Equity Details
Price & Market Data
Price: $5.28
Daily Change: -$0.16 / 3.03%
Daily Range: $5.26 - $5.57
Market Cap: $870,003,904
Daily Volume: 2,180,097
Performance Metrics
1 Week: 1.81%
1 Month: -15.29%
3 Months: 5.84%
6 Months: 24.59%
1 Year: 171.3%
YTD: 4.80%
About Annexon, Inc. (ANNX)
Understand the dynamics of Annexon, Inc. (ANNX). The stock is at 5.28, showing a -$0.16 / 3.03% change today. Market cap: 870,003,904. Performance over 1-week (1.81%) and 3-month (5.84%) periods are highlighted.
Company Details
Employees: 96
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
